ShangBay Capital is a venture capital firm based in Palo Alto, California, founded in 2015, specializing in early-stage investments in medical devices, biotechnology, and healthcare technology sectors. The firm focuses on companies addressing significant unmet clinical needs, leveraging its extensive industry experience and network to support portfolio companies.

As of November 2024, ShangBay Capital has invested in 87 companies, including Fluid Biomed, Venova Medical, and Aveta System, with a total of 17 successful exits. The firm has a combined 100+ years of experience and has established deep ties with strategics and innovators in disruptive technologies.